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SUMMARY 
Purpose: Roberts Syndrome (RBS) is a rare recessively-transmitted developmental 
disorder characterized by growth retardation, craniofacial abnormalities and 
truncation of limbs. All affected individuals to date have mutations in the ESCO2 
(Establishment of cohesion 2) gene, a key regulator of the cohesin complex, which is 
involved in sister chromatid cohesion and DNA double-strand break (dsb) repair. 
Here we characterize DNA damage responses (DDRs) for the first time in a RBS-
affected family.  
Methods and Materials: Lymphoblastoid cell lines (LCLs) were established from an 
RBS family, including the proband, and parents carrying ESCO2 mutations. Various 
DDR assays were performed on these cells, including clonogenic, chromosome 
break and apoptosis assays, checkpoint activation indicators and measures of DNA 
breakage and repair. 
Results: Cells derived from the RBS-affected individual showed sensitivity to 
ionizing radiation (IR) and Mitomycin C (MMC) -induced DNA damage. In this 
ESCO2 compound heterozygote, other DNA damage responses were also 
defective, including enhanced IR-induced clastogenicity and apoptosis, increased 
DNA dsb induction and a reduced capacity for repairing IR -induced DNA dsbs as 
measured by γ-H2AX foci and the comet assay.  
Conclusions: in addition to its developmental features, RBS can be, like ataxia 
telangiectasia, considered a DNA damage response-defective syndrome, which 
contributes to its cellular, molecular and clinical phenotype. 
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INTRODUCTION 
 
Roberts syndrome (RBS) (MIM #268300) is a rare, autosomal recessive disorder 
with prenatal and postnatal growth retardation, distinctive craniofacial 
abnormalities and limb defects; severely affected patients are unlikely to survive 
early childhood (1). The limb abnormalities of RBS are predominantly 
tetraphocomelia (symmetrical limb reduction). Other clinical features include 
mental retardation, cardiac and renal defects. Mutations in an evolutionarily 
conserved gene, ESCO2, are implicated in the aetiology of RBS (2-4). All RBS 
patients studied to date have biallelic mutations of the ESCO2 gene. Of 26 
mutations reported so far, all except one result in the complete or partial loss of 
the C-terminal acetytransferase domain of the ESCO2 protein (2,4). This domain 
is responsible for its canonical enzymatic activity. The ESCO2 gene resides on 
chromosome 8p21.1 and functions as a key regulator of a multi-protein complex 
known as cohesin (McKay et al., 1996; Toth et al., 1999; Vega et al., 2005), 
which is involved in multiple nuclear DNA transactions, including the 
establishment of sister chromatid cohesion during S-phase of the cell cycle, 
transcriptional regulation and DNA dsb repair. Although cohesin dysfunction has 
been implicated in cancer initiation and progression (5,6), cancer-proneness is 
not a feature of RBS, possibly because affected individuals die at an early age 
(http://www.omim.org). 
It has been reported that some RBS patients’ cells show hypersensitivity to DNA 
damaging agents causing DNA dsbs, such as ionizing radiation (IR) and mitomycin C 
(MMC) (7,8). Another study reported hypersensitivity of RBS fibroblasts to mitomycin C 
and camptothecin, but not to IR (9). In addition to the lack of agreement on cellular 
sensitivities to DNA damaging agents there is limited information on the molecular 
mechanisms underlying the limited DDR phenotypes described to date in RBS. We 
report here the first DDR analysis of a RBS family, i.e. including parents carrying 
ESCO2 heterozygous mutations and provide evidence for penetrance of the cellular 
sensitivity to IR.  
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 2 
MATERIALS AND METHODS  
Cell lines, DNA sequencing, and chromosome banding  
 Lymphoblastoid cell lines (LCLs) were established from peripheral blood mononuclear 
cells from the RSB-affected individual, her parents and a non-related control by Epstein-
Barr Virus-transformation (10). Cells were maintained in RPMI-1640 medium, containing 
20% fetal bovine serum (FBS) at 370C under 5% CO2. Genomic DNA was extracted 
using a DNeasy Blood and Tissue Kit (Qiagen, USA). Mutation screens of ESCO2 was 
performed by PCR amplification of all coding exons and intron-exon boundaries 
followed by Sanger sequencing with BigDye Terminator v3.1 cycle sequencing, and 
analyzed on an ABI 3730 (Applied Biosystems, USA). Chromosome banding was 
analysed the by Victorian Cytogenetic Services (Melbourne, Victoria, Australia). 
 
Cell survival assay 
Cell survival analyses were performed essential as described previously (11). 
Briefly, LCLs in exponentially growing phase from RSB-affected individual, 
parents and a non-related control were treated with IR or Mitomycin C (MMC). To 
determine radiosensitivity, cells were irradiated on ice with a graded dose of 
gamma radiation (0, 1, 2, and 3 Gy) from a 137Cs source at a dose rate of 0.56 Gy 
per minute. Cell apoptosis was determined at 24 hr post -radiation by FACS 
analysis of sub-G1-phase cells. For survival analysis, cells were cultured for 
96 hr, and cell viability was determined with a tetrazolinium salt WST-1 [2-(4-
Iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium] (Roche 
Applied Science, Indianapolis, IN). The fraction of cell survival was expressed as 
a ratio of surviving cells to unirradiated cells. To determine MMC sensitivity, cells 
were treated with a graded dose of MMC (0, 0.1, 0.2, 0.3, 0.4 and 0.5 mM) for 24 
hours. Following washing in phosphate buffered saline (PBS), cells were 
incubated at 370C under 5% CO2 for 96 hr. Cell viability was determined as 
described above. Three independent experiments, each with four replicates, were 
performed for each data point. Survival curves were fitted by nonlinear regression 
analysis with the exponential model (Prism version 5.01, GraphPad Software, 
San Diego, California USA).  
 
γ-H2AX focus analysis 
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 3 
γ-H2AX focus detection and analysis of DSB repair kinetics was performed as 
described (12). Briefly, cells in exponential phase of growth were washed twice 
with PBS and resuspended (0.7 million cells per ml of media) in fresh RPMI-1640 
medium (Invitrogen) with 10% FBS. Cells were kept on ice for 10 mins and 
exposed to 0 and 2 Gy of gamma radiation from a 137Cs source at a dose of 
0.56Gy per minute. Cells were returned to 370C for 1 hr, 2 hr and 4 hr time points, 
whereas cells for the zero time point were processed for immunoflorescence (IF) 
staining immediately. For IF staining, 100 uL of cell suspension was dispensed 
onto polylysine slides (Menzel-Glaser, Germany) using a cytospin funnel, and 
spun at 500rpm for 5 minutes. Cells were fixed at room temperature (RT) for 5 
minutes using 4% paraformaldehyde (Sigma-Aldrich, St Louis, MO, USA). Slides 
were washed twice with PBS, permeabilized in 0.1% Triton-X 100 and blocked 
with 1% BSA for 30 minutes at RT. Slides were then incubated for 2 hours at RT 
with anti-γ-H2AX mouse monoclonal antibody (1:500 dilution in 1% BSA, Merck, 
Germany). Following three washes in PBS, cells were incubated at RT for 1 hour 
with secondary antibody (Alexa-488 diluted 1:500 in PBS, Sigma-Aldrich). Cells 
were washed three times in PBS and DNA was stained using 4’,6-diamidino-2-2-
phenylindole (DAPI). Images were acquired using a x60 oil immersion objective 
on an Olympus IX81 microscope with Z-stage (Olympus, Japan) and Metamorph 
software for image acquisition and processing (Molecular Devices, CA, USA). 
Eight to ten Z-sections were acquired for each field and were deconvoluted for 
counting the foci. For each experiment, foci were counted in approximately 100 
cells from 4 to 5 microscopy fields using a constant threshold value. Two 
independent experiments were analyzed except for the 2 hr time point. 
 
Comet assay 
Comet assay and analysis of dsb repair kinetics was performed as described 
previously (11). Briefly, LCLs were irradiated on ice with 8 Gy of gamma 
irradiation at a dose rate of 0.56 Gy per minute. Cells were harvested 0, 1 and 
4 hr after irradiation. Unirradiated cells were used as a control for the basal level 
of DNA damage. The comet assay for the detection of DSBs was performed in 
neutral lysis buffer essentially as described (13). Cell lysis was performed in 
neutral lysis buffer (2M NaCl, 30 mM Na2EDTA, 10 mM Tris-HCl, 1% Sarkosyl, 
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1% Triton X-100, and 10% DMSO [pH 8.3]), and electrophoresis was carried out 
in TBE buffer (2 mM Na2EDTA, 90 mM Tris-HCl and 90 mM Boric acid [pH 8.3]). 
DNA damage was measured as the tail moment (tail moment = [(tail length × tail 
DNA intensity)/entire cell DNA intensity (head and tail)] × 100) with CASP image 
analysis software (http://casp.sourceforge.net). For each data point, eight to ten 
images were captured. Tail moments were measured for all cells, and doublets in 
each image were excluded. The mean of tail moment was calculated with a 
minimum of 50 cells per data point. 
 
Sister chromatid break assays 
Cells for sister chromatid break analysis were irradiated with 0.6 Gy from a 137Cs source 
at a dose of 0.56Gy per minute on ice and allowed to recover at 370C for 30 min. Cells 
were incubated in colcemid (0.1g/ml) at 370C for 60 min. Chromosome spreads were 
prepared as described previously (14). Chromatid and chromosome breaks were scored 
as described (15). 
 
Western blot analysis, immunoprecipitations 
Cells in the exponential phase of growth were exposed to 0 and 1 Gy of gamma 
radiation from a 137Cs source at a dose of 0.56Gy per minute on ice. Cells were 
returned to 370C for 1 hr, 2 hr and 4 hrs, whereas cells for the t=0 time point were 
washed in PBS and proceeded to protein extraction immediately. For histone 
extraction, cells were lysed in PBS containing 0.5% Triton X 100, 2 mM PMSF 
and 0.02% NaN3 10 min on ice, followed by centrifugation at 10,000 rpm for 1 
minute at 4°C. Cells were incubated in extraction b uffer (0.5N HCl + 10% 
glycerol) on ice for 30 minutes. Following centrifugation at 12,000 rpm for 5 
minutes at 4°C, cell pellets were kept in acetone a t –20°C overnight. Following 
air-drying of the pellet, distilled water was added and protein concentration 
determined using the bicinchoninic acid assay (BCA assay) (Thermofisher 
Scientific). Western blot analyses were as described previously (5). 
Immunoprecipitation of ATM proteins was performed as described previously 
(16). Briefly, cell extracts were prepared by lysing cells for 45 min at 4 °C in ATM 
kinase lysis buffer containing 0.2% Tween 20, 1 mMNa3VO4, 1 mM NaF, 10 
mMNa2MoO4, 20 mMβ-glycerophosphate, 5 µM microcystin-LR, 5 nM okadaic 
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 5 
acid, 5 µg/ml each of aprotinin, leupeptin, and pepstatin, 1 
mM phenylmethylsulfonyl fluoride, and 1 mM dithiothreitol. Cell lysates were 
precleared in protein A/G-Sepharose, and used for immunoprecipitation with 
sheep polyclonal ATM antibodies overnight with constant mixing. Immune 
complexes were adsorbed onto protein G-Sepharose, washed, and resolved on 
SDS gels (5% acrylamide). After transfer to nitrocellulose membranes, they were 
probed consecutively with phospho-Ser367 ATM, phospho-Ser1981 ATM, and 
phospho-Ser1893 ATM antibodies with stripping between each step. 
  
Statistical analysis 
Analysis of cell survival was performed using regression analysis and statistical 
significance was analysed using the F-test (GraphPad Prism v5.01). For γ-H2AX focus 
and COMET analyses, paired Student t-Tests were performed. 
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 6 
RESULTS 
 
The RBS family and ESCO2 mutation analysis 
A female neonatal patient with a phenotype typical of RBS is presented. The affected 
individual had truncation of all limbs (Figure 1A), with bones distal to the flexures more 
severely affected. Toes and fingers were dysmorphic and the patient had a cleft lip and 
palate. The parents were phenotypically normal. The proband’s chromosome analysis 
showed centromeric heterochromatin repulsion characteristic of, and confirming, the 
diagnosis of RBS (Figures 1B-D). Pathogenic compound heterozygous ESCO2 
mutations were identified in the patient. A c.760_761insA mutation (NM_001017420.2) 
predicting a truncating mutation p.(Thr254Asnfs*26) or p.(T254Nfs*26) in exon 3 and 
this mutation was identified in the father’s blood sample (Figure 1E). A second 
mutation, c.1132-7A>G (NM_001017420.2), as predicted by three in silico programs 
MaxEntScan, NNSPLICE and Splice Site Finder (SSF) to change the splice acceptor 
site 7 bp downstream to create a cryptic splice acceptor site at the splice region of intron 
6, resulting in an addition of one amino acid followed by a stop codon 
p.(Ile377_Asp378insLeu*) or p.(I377_D378insL*) (Figure F and G). This mutation was 
detected in the mother’s blood sample (Figure F and G). RNA study confirmed the 
presence of aberrantly spliced transcripts in lymphocytes of the patient and the mother 
(Figure H). Both c.760_761insA and c.1132-7A>G mutations are present in the 
population at low frequencies of approximately 0.034% and 0.002% as recorded by 
gnomAD, and predict a truncated ESCO2 protein by approximately 57% and 37% 
resulting in loss of the acetyltransferase domain. The compound mutations have 
previously been reported in an Italian RBS family(2). 
 
DNA damage response 
After genotoxic trauma, mammalian cells exhibit a number of responses, including DNA 
repair, cell death and DNA damage checkpoint activation. We exposed LCLs derived 
from the patient, parents and a control individual to graded doses of IR, which induces 
DNA dsbs (and other DNA lesions), which are key mutagenic, clastogenic and lethal 
lesions induced by IR (17). The results showed significant reduction in survival of patient 
cells following IR, although not to the same extent as LCLs from a patient carrying 
homozygous mutations in the ATM gene, which were exquisitely IR-sensitive (Figure 
2A). Cells from the heterozygous parents exhibited wild-type sensitivity to IR (Figure 
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 7 
2A). Likewise, treatment of LCLs with the DNA inter-strand cross-linking agent, MMC, 
also repaired at least partially by the DNA dsb repair machinery, resulted in a 
significantly reduced survival for patient cells (p<0.05)(Figure 2B).  
We determined the susceptibility of the different cell lines to IR-induced cell death.  
Untreated cells from the patient and the father had significantly higher levels of 
apoptosis, suggesting their cellular instability (Figure 2C). Cells from the patient 
displayed a significant increase in apoptosis following a 2Gy dose of IR, which was most 
prominent at 24 hr (Figure 2C). Furthermore, patient cells exhibited a marked increase 
in sister chromatid breaks post 0.6 Gy IR (Figure 2D). Such a phenotype would be 
consistent with an inability to properly repair DNA dsbs. The latter phenotype was not 
evident in cells from the carriers (Figure 2D). 
 
DNA damage checkpoints after IR  
We next evaluated the ability of RBS patient cells to activate the DNA damage response 
following IR. DNA damage-induced phosphorylation of p53 at Ser15 was detected 1 hr 
post IR in patient cells, both parent cells and the control unaffected cells (Figure 3A). 
The p53S15 signal had largely diminished by 4 hr in the control and both heterozygous 
carriers, while it remained unchanged in patient cells (Figure 3A). The data are 
consistent with an adequate activation of the p53 checkpoint in RBS cells. Since p53 is 
phosphorylated at Ser15 by ATM (mutated in ataxia-telangiectasia) in response to IR 
(18), we determined whether ATM was activated in the patient’s cells following IR. 
Previous reports have shown that autophosphorylation is associated with ATM’s 
activation in human cells (19). Autophosphoration of ATM at three common sites, S367, 
S1893 and S1981, was evident in patient cells following IR (Figure 3B). Although a 
weaker signal of phosphorylated ATM in patient cells was observed, this is co-incident 
with a weaker signal on total immunoprecipitated ATM. Therefore, we considered that 
ATM activation is unlikely to be adversely affected in the patient cells. Likewise, ATM-
mediated DNA damage-induced phosphorylation of cohesin SMC1A (an ATM 
phosphorylation target) at Ser957 was detected in the patient cells (Figure 3C). 
Together, the data suggest that these ESCO2 mutations have no apparent affect on the 
activation of the ATM-mediated DNA damage responses but that these cells are 
hypersensitive to agents that lead to DNA dsbs. 
 
DNA dsb induction and repair 
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 8 
In view of their increased sensitivity to IR and MMC and IR-induced clastogenicity, we 
evaluated the ability of ESCO2 mutant cells to repair IR-induced DNA damage, by 
determining the induction and repair of the γ-H2AX protein, which serves as a marker for 
dsbs (20-22), over three different time points post IR. On semi-quantitative Western blot 
analysis, an elevated level of γ-H2AX was detected 1 hr post IR in irradiated cells of all 
genotypes (Figure 4A). By 4 hr post IR, the signal intensity of γ-H2AX was significantly 
reduced in normal control and both parental heterozygous mutant cell lines. In contrast, the 
γ-H2AX signal persisted at a high level in patient cells (Figure 4A). These data suggest 
defective DNA dsb repair in the patient’s cells, most of which ordinarily occurs by 4 hours 
post-induction (23,24).  
Since heterozygous cells exhibited IR-induced γ-H2AX changes that were similar to 
ESCO2 WT control cells, we focussed on the patient cells for subsequent assays. The 
kinetics of DNA dsb induction and repair was further evaluated by quantitative analyses 
of γ-H2AX foci following IR (Figure 4B). No statistically significant differences were 
detected in the basal level of γ-H2AX foci in unirradiated cells in any genotype. At 1 hr 
post IR, the typical and marked increase in the number of γ-H2AX foci was observed 
and this was followed by a decrease at 2 hr and 4 hr post IR in both patient and control 
cell lines (Figure 4B). Although the kinetics of γ-H2AX focus resolution were similar in 
patient and control cells, there were more residual γ-H2AX foci in patient cells, 
consistent with the γ-H2AX levels as detected on Western blots. 
 
We further evaluated the potential DNA repair defect of RBS patient cells using the 
neutral ‘comet’ assay, which preferentially allows for the detection of DNA dsbs at the 
whole cell level (Figure 4C). RBS patient cells showed a significantly higher basal level 
of dsbs (Figure 4D), suggesting instability. Following IR, control cells exhibited a 
marked reduction in dsbs at 1 hr post IR; by 4 hr post IR, dsb quantities were 
comparable to the basal level. In contrast, dsbs remained at a high level in patient cells 
even after 4 hrs (Figure 4E). 
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 9 
DISCUSSION 
Roberts Syndrome (RBS) is a rare, recessively-inherited genetic disorder. Its 
canonical clinical features include growth retardation, truncation of the limbs and 
craniofacial abnormalities. A number of Mendelian disorders manifest the latter 
characteristic, along with clinical or in vitro radiosensitivity (Table 1). These disorders 
are characterized in most cases by autosomal recessive inheritance and by structural or 
functional facial abnormalities. Many different genes are responsible.  
Here we report for the first time, the characterization of the cellular DNA damage 
response (DDR) in a RBS kindred. Our affected case showed the typical clinical and 
cytogenetic features (Figure 1) characteristic of the disorder. We demonstrated that 
mutations affecting the acetyltransferase domain of the ESCO2 gene present in the 
patient were inherited from her parents. The affected individual manifested multiple 
cellular abnormalities of the DDR. 
The first mammalian components of the cohesin complex were discovered over two 
decades ago (24). Cohesin proteins have major roles in a number of fundamental 
molecular processes, including sister chromatid cohesion, transcriptional control and 
DNA dsb repair. In recombinational repair of DNA dsbs, there is genetic and 
biochemical evidence from multiple species that cohesin accumulates around the site of 
the dsb and stabilizes it for subsequent enzymatic activity by homologous recombination 
enzymes (25-28). Cohesin is a multiprotein complex with four core components: 
RAD21, SMC1 (structural maintenance of chromatin 1), SMC3 and an SA (stromal 
antigen) subunit (either SA1, SA2 or SA3); numerous cohesin-associated and cohesin-
regulator proteins are now known, including ESCO2 (29). 
Transfer of an acetyl group is important for various protein-protein interactions. The 
acetyltransferase activity of the ESCO2 protein is required for the acetylation of the core 
cohesin component SMC3 (30). This has been shown to be essential for the localization 
of cohesin to chromosomes (pericentric heterochromatin) (31) and for the establishment 
of sister chromatid cohesion during DNA replication (32). 
We characterized DDRs in a RBS-affected family. The RBS-affected 
individual showed clear evidence of chromosomal instability and increased 
sensitivity to IR and mitomycin-C. This finding is consistent with a previous report 
of increased sensitivity to DNA damaging agents, including IR, in fibroblasts 
derived from RBS patients (7), but differed from another report, which 
demonstrated that RBS cells were sensitive to several DNA damaging agents, 
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failed to show their sensitivity to IR (8). It is possible that the genotoxin-sensitivity 
phenotype is mutation-dependent. Also, mutations in RAD21, a member of the 
cohesin complex, led to chromosomal aberrations and radiosensitivity in humans 
(11) and genetically engineered mice (14). In addition, reducing cohesin levels 
had a greater impact on chromosome condensation, repetitive DNA stability and 
DNA repair compared to that on sister-chromatid cohesion and chromosome 
segregation (33). A lack of cohesin in meiosis leads to the accumulation of 
deleterious DNA dsbs (34). Collectively, these data support a role for the cohesin 
complex and its regulators in DNA (dsb) repair.  
The work described here strongly suggests that the cells of the ESCO2 homozygous 
patient are defective in DNA dsb repair. This was shown directly in multiple assays, 
including chromosome/chromatid break assay, γH2AX Western blots and 
immunofluorescence and neutral comet assay, and indirectly with IR and MMC-
clonogenic survival. Increased sensitivity to IR of the RBS cells did not appear to be due 
to a defect in ATM activation or signaling through its downstream substrates. 
Our data suggest that the acetyltransferase activity of ESCO2 is likely required for 
the repair of DNA dsbs. Since cohesin loading to the sites of DNA breaks is required for 
efficient DNA repair, the observed DNA repair defect in RBS–affected cells is likely due 
to a defective function of ESCO2 in facilitating cohesin loading onto chromatin following 
DNA damage. 
In addition to its developmental features, RBS can hence be considered a disorder 
of the DDR, including defective repair of DNA dsbs. The affected gene, ESCO2, is a 
DDR gene at a number of levels, and specifically, a new addition to the list of human 
DNA dsb repair genes.  
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FIGURE LEGENDS 
 
Figure 1. A. The RBS patient. B-D. Representative metaphase chromosome spreads 
from the RBS patient, exhibiting characteristic heterochromatin splaying / repulsion 
(arrowed and one example in each enlarged) on solid-stained B, G-banded C and C-
banded spreads D, E, F.  DNA chromatograph of mutations detected in mother, father 
and proband. G. Predicted change of the acceptor site by the c.1132-7A>G mutation. D. 
Asparatic acid; A. Alanine; X. Stop codon. L. Leucine. H. PCR detection of aberrantly 
spliced transcripts in RNA from lymphocytes of mother and proband but not in the 
control.  
 
Figure 2. Genotoxin sensitivity of cells from the different RBS genotypes. ‘AT-cells’ are 
from an ataxia-telangiectasia compound heterozygote.  LCLs of the different genotypes 
treated with graded doses of IR (A), or with MMC (B), three independent replicate 
experiments for each cell line. C. IR-induced apoptosis, duplicate experiments for each 
cell line. Each cell line was subjected to 2Gy and resulting apoptosis % determined. D. 
Low-dose (0.6Gy) IR-induced clastogenicity. Arrows show sister chromatid breaks. Sb, 
sister chromatid breaks; Cb, chromosome breaks; Int, interchanges; ICA, induced 
chromosome aberrations/metaphase. Duplicate experiments. 
 
Figure 3. Activation of cell cycle checkpoints in RBS and control cells after IR 
exposures. A. p53 serine 15 phosphorylation after 2Gy IR to cells of the four genotypes. 
Top panel: anti-p53, serine 15. Bottom panel: anti-pan actin control. B. ATM activation 
at various phosphorylation sites in RBS and control cells after 3Gy IR. Top panel: ATM 
phosphorylation sites S367, S1893 and S1981 were examined with or without IR. C2: 
control 2. Bottom panel: Loading control: sheep IgH. C. SMC1A cohesin 
phosphorylation in RBS cells after 3Gy IR.  Bottom panel: Total SMC1A protein lane 
loading. Images are representative of at least duplicate experiments. 
 
Figure 4. Kinetics of induction and repair of DNA dsbs in RBS cells after ionizing 
radiation. A. γ-H2AX levels in control and RBS cells after 1Gy ionizing radiation, as 
assayed by Western blot analysis. Histone 3 was a loading control. B. Appearance and 
time-course of γ-H2AX foci in control and RBS cells after IR. C. ‘Comet’ assay showing 
unirradiated and irradiated (+6Gy) cells. Damaged DNA (tail) was quantitated relative to 
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intact DNA (head). D and E. Quantitation of DNA dsbs at the basal level (D) (* p<0.05.) 
and post IR (E). Images and graphs are representative of at least duplicate 
experiments. 
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Table 1. Human syndromes characterized by facial abnormalities and 
radiosensitivity.  
 
Syndrome 
 
 
Gene 
 
Locus 
 
Inheritance 
 
Facial features 
 
Roberts 
 
ESCO2 
 
8p21.1 
 
Recessive 
 
Cleft palate and lip 
 
 
Ataxia-
telangiectasia 
 
ATM 
 
11q22.3 
 
Recessive 
 
Choreiform facial movements; Dysarthric speech; 
Ocular telangiectasia 
 
 
Ataxia-
telangiectasia 
-Like 
 
MRE11 
 
11q21 
 
Recessive 
 
Dysarthric speech; Ocular telangiectasia 
 
RIDDLE 
 
RNF168 
 
3q29 
 
Recessive 
 
Facial dysmorphism; Ocular telangiectasia 
 
 
Ligase IV 
 
LIGIV 
 
13q33.3 
 
Recessive 
 
Facial dysmorphism 
 
 
Nijmegen 
Breakage 
 
NBS1 
 
8q21.3 
 
Recessive 
 
Choreiform facial movements; Dysarthric speech; 
Ocular telangiectasia 
 
 
Ataxia, adult onset, 
with oculomotor 
apraxia 
 
APTX 
 
9p21.1 
 
Recessive 
 
Choreiform facial movements; oculomotor apraxia 
 
Basal cell naevus 
 
PTCH1, 
PTCH2, 
SUFU 
 
9q22.32, 
1p24.1, 
10q24.32 
 
Dominant 
 
Broad facies; Frontal bossing; Mandibular 
prognathism; Odontogenic keratocysts of jaws; 
Strabismus; Lateral displacement of the inner 
canthi; Hypertelorism; Iris coloboma; Broad nasal 
root; Cleft lip and palate  
 
Data from Online Mendelian Inheritance in Man (https://www.omim.org/). 
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